 Total androgen ablation European experience EORTC GU Group Zoladex time progression subjective objective first progression orchiectomy difference survival death causes malignant disease delay appearance progression survival fact duration survival progression Zoladex evidence survival benefit Zoladex quality control data acknowledged problems responses patients advanced prostate cancer review Bone Scan Committee data Tables data reflections heterogeneity studied patient population Table pain response weeks many items committees response criteria quality life trials similar problems work patience firm answer clinical problem efforts combined results trials knowledge treated history prostate cancer net treatment benefit subsets patients treatment patient anonymous mass cases advanced prostate cancer reward continued collaboration study groups